Cargando…

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia

Lipoprotein-apheresis (apheresis) removes LDL-cholesterol in patients with severe dyslipidemia. However, reduction is transient, indicating that the long-term cardiovascular benefits of apheresis may not solely be due to LDL removal. Microparticles (MPs) are submicron vesicles released from the plas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Connolly, Katherine D., Willis, Gareth R., Datta, Dev B. N., Ellins, Elizabeth A., Ladell, Kristin, Price, David A., Guschina, Irina A., Rees, D. Aled, James, Philip E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society for Biochemistry and Molecular Biology 2014
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173999/ https://www.ncbi.nlm.nih.gov/pubmed/25121984 http://dx.doi.org/10.1194/jlr.M049726

Ejemplares similares

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection
por: Julius, Ulrich
Publicado: (2016)

Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis
por: Fahed, Akl C., et al.
Publicado: (2012)

Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia
por: Wang, Anthony, et al.
Publicado: (2016)

Improvement of oxidative stress status by lipoprotein apheresis in Chinese patients with familial hypercholesterolemia
por: Wen, Jun, et al.
Publicado: (2019)

Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis center
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

An update on lipid apheresis for familial hypercholesterolemia
por: Taylan, Christina, et al.
Publicado: (2022)

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia
por: Puntoni, Mariarita, et al.
Publicado: (2011)

Usefulness of Lipid Apheresis in the Treatment of Familial Hypercholesterolemia
por: Lui, Matthew, et al.
Publicado: (2014)

Successful Direct Adsorption of Lipoproteins (DALI) Apheresis During Pregnancy in an Omani Woman with Homozygous Familial Hypercholesterolemia
por: Al-Dughaishi, Tamima, et al.
Publicado: (2015)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease
por: Heigl, Franz, et al.
Publicado: (2015)

Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients
por: Víšek, J., et al.
Publicado: (2021)

Long-Term LDL-Apheresis Treatment and Dynamics of Circulating miRNAs in Patients with Severe Familial Hypercholesterolemia
por: Dlouha, Dana, et al.
Publicado: (2023)

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab
por: Tanaka, Akihito, et al.
Publicado: (2017)

Characterisation of adipocyte-derived extracellular vesicles released pre- and post-adipogenesis
por: Connolly, Katherine D., et al.
Publicado: (2015)

The effect of DALI lipid apheresis in the prognosis of homozygous familial hypercholesterolemia: Seven patients' experience at a DALI apheresis center
por: Bulut, Muhammet, et al.
Publicado: (2020)

HELP LDL Apheresis Reduces Plasma Pentraxin 3 in Familial Hypercholesterolemia
por: Zanetti, Michela, et al.
Publicado: (2014)

Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia
por: Varga, Viktória E., et al.
Publicado: (2016)

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
por: Greco, Maria Francesca, et al.
Publicado: (2020)

Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis
por: Weylandt, Karsten-H., et al.
Publicado: (2019)

Lipoprotein apheresis efficacy and challenges: single center experience
por: Özdemir, Zehra Narlı, et al.
Publicado: (2022)

Low-density lipoprotein apheresis in a pediatric patient of familial hypercholesterolemia: Primi experientia from a tertiary care center in North India
por: Dogra, Kanchan, et al.
Publicado: (2017)

Just not cosmesis! Role of low-density lipoprotein apheresis in familial hypercholesterolemia: Experience at a newly developed tertiary care institution in Northern India
por: Kaur, Daljit, et al.
Publicado: (2021)

The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on
por: Schettler, V. J. J., et al.
Publicado: (2017)

The Impact of Lipoprotein Apheresis on Oxidative Stress Biomarkers and High-Density Lipoprotein Subfractions
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

LDL apheresis in a woman with severe heterozygous familial hypercholesterolemia. Late, but not too late
por: Mickiewicz, Agnieszka, et al.
Publicado: (2015)

Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia
por: Lischka, Julia, et al.
Publicado: (2022)

Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients
por: Julius, Ulrich
Publicado: (2018)

Circulating Endothelial Progenitor Cell and Platelet Microparticle Impact on Platelet Activation in Hypertension Associated with Hypercholesterolemia
por: Alexandru, Nicoleta, et al.
Publicado: (2013)

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
por: Matta, Anthony, et al.
Publicado: (2021)

Generation of Platelet Microparticles after Cryopreservation of Apheresis Platelet Concentrates Contributes to Hemostatic Activity
por: Eker, İbrahim, et al.
Publicado: (2017)

Lipoprotein metabolism in familial hypercholesterolemia
por: Chemello, Kévin, et al.
Publicado: (2021)

HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures
por: Buuren, Frank van, et al.
Publicado: (2012)

The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina
por: Khan, Tina Z, et al.
Publicado: (2014)

Use of CMR imaging to assess the effect of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a)
por: Khan, Tina, et al.
Publicado: (2015)

Homozygous familial hypercholesterolemia with stenosis of the left anterior descending coronary artery successfully treated with weekly low‐density lipoprotein apheresis for 16 years without percutaneous coronary intervention
por: Yasu, Takanori, et al.
Publicado: (2019)

Changes in Lipids and Lipoproteins after Selective LDL Apheresis (7-Year Experience)
por: Kolovou, Genovefa, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_in7hiphsp43d152dm7iq0fclbh